title: Patterns and effectiveness of bortezomib use according to age in the VESUVE cohort.
abstract: Therapeutical options for older multiple myeloma patients have been improved with the advent of new drugs, yet there is a lack of observational data for such patients. To address this issue, an age-stratified analysis of the VESUVE cohort of bortezomib users was performed. Among the 779 patients included in the analysis, 358 (46%) were aged ≤ 65 years, 282 (36%) were between 65-75 years and 139 (18%) were more than 75 years old. There were few significant differences in treatment parameters across age groups; notably, older patients received a lower dose of bortezomib and more frequently experienced general or administration site conditions, metabolism or nutrition disorders and cardiac disorders. Overall best response rate and progression-free survival were similar across age groups. Taken together, these results indicate that older patients do benefit from bortezomib and that tailored treatment in real-life clinical practice does not compromise effectiveness.
authors.affiliation: a Inserm CIC1401 , Bordeaux , France ;|b Univ. Bordeaux , Bordeaux , France ;
authors.forename: Angela
authors.initials: A
authors.lastname: Grelaud
authors.affiliation: a Inserm CIC1401 , Bordeaux , France ;|b Univ. Bordeaux , Bordeaux , France ;|c Inserm U657 , Bordeaux , France ;|d CHU Bordeaux , Bordeaux , France ;
authors.forename: Annie
authors.initials: A
authors.lastname: Fourrier-Réglat
authors.affiliation: e Polyclinique Bordeaux Nord , Bordeaux , France ;
authors.forename: Olivier
authors.initials: O
authors.lastname: Fitoussi
authors.affiliation: f CHU Lille , Lille , France ;
authors.forename: Thierry
authors.initials: T
authors.lastname: Facon
authors.affiliation: a Inserm CIC1401 , Bordeaux , France ;|b Univ. Bordeaux , Bordeaux , France ;
authors.forename: Jérémy
authors.initials: J
authors.lastname: Jové
authors.affiliation: c Inserm U657 , Bordeaux , France ;|g CHU Rouen , Rouen , France.
authors.forename: Jacques
authors.initials: J
authors.lastname: Bénichou
authors.affiliation: a Inserm CIC1401 , Bordeaux , France ;|b Univ. Bordeaux , Bordeaux , France ;
authors.forename: Philip
authors.initials: P
authors.lastname: Robinson
authors.affiliation: d CHU Bordeaux , Bordeaux , France ;
authors.forename: Gérald
authors.initials: G
authors.lastname: Marit
authors.affiliation: a Inserm CIC1401 , Bordeaux , France ;|b Univ. Bordeaux , Bordeaux , France ;
authors.forename: Magali
authors.initials: M
authors.lastname: Rouyer
authors.affiliation: a Inserm CIC1401 , Bordeaux , France ;|b Univ. Bordeaux , Bordeaux , France ;|c Inserm U657 , Bordeaux , France ;|d CHU Bordeaux , Bordeaux , France ;
authors.forename: Nicholas
authors.initials: N
authors.lastname: Moore
authors.affiliation: a Inserm CIC1401 , Bordeaux , France ;|b Univ. Bordeaux , Bordeaux , France ;|c Inserm U657 , Bordeaux , France ;|d CHU Bordeaux , Bordeaux , France ;
authors.forename: Pernelle
authors.initials: P
authors.lastname: Noize
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D000069286:Bortezomib / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D015331:Cohort Studies; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D009367:Neoplasm Staging; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D000069286:Bortezomib
keywords: Bortezomib; aged; cohort studies; multiple myeloma; survival analysis